Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA vs IA in Newly Diagnosed AML
NCT07486479Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07486479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486479.